Drug intelligence / Profile preview

BMS-986196

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

BMS-986196 is an investigational small molecule drug developed by Bristol Myers Squibb. It functions as a Bruton’s tyrosine kinase (BTK) inhibitor, targeting the BTK enzyme involved in B-cell receptor signaling. The drug is being studied primarily for the treatment of multiple sclerosis (MS), with clinical trials focused on evaluating its safety, tolerability, pharmacokinetics, and central nervous system penetration in both healthy volunteers and patients with MS. Radiolabeled forms such as 11C-BMS-986196 have also been used to assess brain distribution via PET imaging[1][3][5][6].

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on BMS-986196.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986196.

Explore the full profile